Global Immunotherapy for Neuroblastoma Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Immunotherapy for Neuroblastoma Market Insights, Forecast to 2034
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
Market Analysis and InsightsGlobal Immunotherapy for Neuroblastoma Market
Global Immunotherapy for Neuroblastoma market is expected to reach to US$ 48 million in 2024, with a positive growth of %, compared with US$ 45 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Immunotherapy for Neuroblastoma industry is evaluated to reach US$ 63 million in 2034. The CAGR will be 4.6% during 2024 to 2034.
Globally, Immunotherapy for Neuroblastoma key companies include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Immunotherapy for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034 and the share will be % in 2034. Moreover, China, plays a key role in the whole Immunotherapy for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.
Immunotherapy for Neuroblastoma can be divided into Dinutuximab, Naxitamab and Other,, etc. Dinutuximab is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2034.
Immunotherapy for Neuroblastoma is widely used in various fields, such as Hospital, Clinic and Other,, etc. Hospital provides greatest supports to the Immunotherapy for Neuroblastoma industry development. In 2022, global % revenue of Immunotherapy for Neuroblastoma went into Hospital filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global Immunotherapy for Neuroblastoma market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Immunotherapy for Neuroblastoma market with multiple angles. Items like regional revenue from 2018 to 2034 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Segment by Type
Dinutuximab
Naxitamab
Other
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2034
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2034 globally
Chapter 5Product revenue analysis by application from 2018 to 2034 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2034 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product revenue analysis by type and application from 2018 to 2034 in Europe. Product revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product revenue analysis by type and application from 2018 to 2034 in China. Product revenue analysis of China from 2018 to 2034
Chapter 9Product revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Companies’ outline, covering company’s basic information, major business, Immunotherapy for Neuroblastoma introduction, etc. Immunotherapy for Neuroblastoma Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12QYResearch’s Conclusions of Immunotherapy for Neuroblastoma
Chapter 13Methodology and Data Sources adopted by QYResearch
Market Analysis and InsightsGlobal Immunotherapy for Neuroblastoma Market
Global Immunotherapy for Neuroblastoma market is expected to reach to US$ 48 million in 2024, with a positive growth of %, compared with US$ 45 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Immunotherapy for Neuroblastoma industry is evaluated to reach US$ 63 million in 2034. The CAGR will be 4.6% during 2024 to 2034.
Globally, Immunotherapy for Neuroblastoma key companies include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Immunotherapy for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034 and the share will be % in 2034. Moreover, China, plays a key role in the whole Immunotherapy for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.
Immunotherapy for Neuroblastoma can be divided into Dinutuximab, Naxitamab and Other,, etc. Dinutuximab is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2034.
Immunotherapy for Neuroblastoma is widely used in various fields, such as Hospital, Clinic and Other,, etc. Hospital provides greatest supports to the Immunotherapy for Neuroblastoma industry development. In 2022, global % revenue of Immunotherapy for Neuroblastoma went into Hospital filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global Immunotherapy for Neuroblastoma market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Immunotherapy for Neuroblastoma market with multiple angles. Items like regional revenue from 2018 to 2034 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Segment by Type
Dinutuximab
Naxitamab
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2034
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2034 globally
Chapter 5Product revenue analysis by application from 2018 to 2034 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2034 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product revenue analysis by type and application from 2018 to 2034 in Europe. Product revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product revenue analysis by type and application from 2018 to 2034 in China. Product revenue analysis of China from 2018 to 2034
Chapter 9Product revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Companies’ outline, covering company’s basic information, major business, Immunotherapy for Neuroblastoma introduction, etc. Immunotherapy for Neuroblastoma Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12QYResearch’s Conclusions of Immunotherapy for Neuroblastoma
Chapter 13Methodology and Data Sources adopted by QYResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices